Navigation Links
Early Coronary Artery Healing Advantage of OrbusNeich's Combo Dual Therapy Stent™ Compared to the TAXUS® Stent Shown in Two Clinical Trial Subgroup Analyses

PARIS, May 17, 2012 /PRNewswire/ -- OrbusNeich today announced that two subgroup analyses from the REMEDEE trial assessing vascular healing of the company's Combo Dual Therapy Stent versus the TAXUS paclitaxel-eluting stent demonstrate an early advantage with the Combo Stent.  Presented at EuroPCR 2012, the data were obtained with frequency-domain optical coherence tomography (FD-OCT) and virtual histology-intravascular ultrasound (VH-IVUS) at nine-month follow-up.

An independent OCT core laboratory performed a blinded quantitative analysis of the percent strut coverage and in stent neointimal characteristics along with a qualitative assessment of neointimal tissue appearance and make-up of 23 Combo Stents and 10 TAXUS stents at nine-month follow-up.

Specifically, the data show that neointimal volumes and thicknesses as measured with OCT were comparable at nine months post-implantation for both the Combo Stent and TAXUS stent as determined by a blinded OCT core lab analysis. However, the qualitative analysis inside the stent showed a more homogenous neointimal tissue appearance in the Combo Stent compared to the TAXUS stent. In detail, the Combo Stent placements had statistically significant more homogeneous tissue appearance compared to the TAXUS stent placements (79.2% versus 40%).  Heterogeneous and layered tissue appearance was observed in 60% of the TAXUS stent placements and in 20.8% of the Combo Stent placements. Additionally, there were fewer microvessels and macrophage-like appearances inside the Combo Stent compared to the TAXUS stent: 8.3% versus 30% microvessels; 4.2% versus 10% macrophage-like appearances.

"These intriguing data possibly demonstrate a more homogenous tissue appearance with the Combo Stent versus a more heterogeneous appearance with the TAXUS stent in a blinded analysis," said Akiko Maehara, M.D.,director of Intravascular Imaging Core Laboratory at the Cardiovascular Research Foundation and assistant professor of medicine at Columbia University College of Physicians and Surgeons in New York. "There is a trend of differences in morphology that may support the Combo Stent's approach of improved vascular healing while maintaining effective control of neointimal proliferation."

A second study evaluated 23 baseline and 15 follow-up VH-IVUS assessments of a subset of patients from the REMEDEE trial to assess the vascular healing response of the Combo Stent compared to the TAXUS stent at nine months. The Combo Stent showed less neointimal proliferation and significantly less confluent necrotic core than the TAXUS stent. The necrotic core volume in the neointimal hyperplasia had an average of 2.8 mm3 in the Combo Stent compared to 4.2 mm3 in the TAXUS stent. Additionally, the Combo Stent had predominantly homogeneous fibrotic neointima.

"The Combo Stent is the only technology that combines the value of endothelial progenitor cell capture to promote vessel healing with an abluminal sirolimus drug elution to limit neointimal proliferation," said Stephen M. Rowland, Ph.D., vice president of research and development at OrbusNeich. "We are committed to bringing innovation to interventional cardiologists to help them address unmet needs with contemporary percutaneous coronary intervention."  

The Combo Stent, the world's first dual therapy stent (DTS), combines an abluminal biodegradable sirolimus elution for the regulation of hyperplasia with Genous™, OrbusNeich's proven endothelial progenitor cell (EPC) capture technology, to accelerate re-endothelialization.

About the Genous Technology

Genous is OrbusNeich's patented EPC capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

The Genous Stent, which has been commercially available in more than 60 countries since 2005, has been proven as a safe, effective alternative to drug eluting stents and is supported by data from more than 7,000 patients in clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous Stent is effective for patients that are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Stent, as well as other stents and balloons marketed under the names of Azule™, R stent, Scoreflex™, Sapphire™, Sapphire II and Sapphire NC. Development stage products include the Combo Dual Therapy Stent, the only dual therapy stent to both accelerate endothelial coverage and control neointimal proliferation through the combination of the Genous pro-healing technology with an abluminal sirolimus drug elution delivered from a biodegradable polymer that achieves full and complete dissipation by 90 days. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit

Follow OrbusNeich on Twitter at, and learn more about the company and the Genous technology on OrbusNeich's YouTube Channel:

Note: OrbusNeich will display its stents at booth N6 at EuroPCR 2012.

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Saving Lives of California Residents Who Develop Skin Cancer Each Year: The Key is Early Detection and Treatment
3. Saving Lives of Florida Residents Who Develop Skin Cancer Each Year: The Key is Early Detection and Treatment
4. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
5. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
6. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
7. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
8. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
9. Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
10. Study Protocols Will be Amended in Two Small Early-Phase Prasugrel Studies
11. Potential Early Warning System for Lung Cancer Identified
Post Your Comments:
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
Breaking Medicine News(10 mins):